Genentech develop Antibiotic with potential to lead to new class of Antibiotics
SMi Reports: Biotech Genentech, discoverers of a promising new antibiotic, are set to speak at this year’s Superbugs & Superdrugs Conference in London, UK on 18th - 19th March 2019.
Despite international efforts to reduce the increasing threat of antibiotic resistance, multi-drug resistant bacteria are continuing to endanger the global population.
Next year's Superbugs & Superdrugs conference (http://www.superbugssuperdrugs.com/pharphorpr), taking place 18th – 19th March in London, aims to explore the efforts of industry-leading organisations in the field, discussing the latest developments in novel therapeutics, antifungals, funding, regulation, and more.
Gram-negative bacteria are considerably the most concerning antibiotic-resistant bacteria, as they have two membranes antibiotics need to penetrate. For a long time, no new classes of antibiotics effective against Gram-negatives had been approved in over fifty years.
However, in recent news US biotech Genentech have developed a molecule called G07750 which has proven effectiveness against several Gram-negative bacteria that are resistant to nearly all marketed antibiotics.* Genentech hopes this discovery will lead to a new class of antibiotics to help aid the fight against the continuous struggle against antimicrobial resistance.
Delegates attending the Superbugs & Superdrugs conference next year in 2019 will have the exclusive opportunity of hearing from Genentech’s Senior Scientist Michael Koehler, who is set to speak and present at the 21st annual event on “Optimized Arylomycins represent a new class of Gram-Negative Antibiotics”.
Michael’s presentation will be focusing on the topics of:
- Chemical optimization of the arylomycins to obtain G0775, a molecule with potent, broad-spectrum activity against Gram-negative bacteria
- G0775 inhibits the essential bacterial type I signal peptidase
- It circumvents existing antibiotic resistance mechanisms and retains activity against contemporary multidrug-resistant Gram-negative clinical isolates
- Optimized arylomycin analogues such as G0775 could translate into new therapies to address multidrug-resistant Gram-negative infections
The development of novel antibiotics is crucial to fighting the war on antibiotic resistance as current treatments fail to effectively treat even the most common and usually innocuous bacterial infections.
Next year’s two-day conference will gather an international speaker line-up to explore the latest advancements in new antimicrobial agents, as well as potential alternatives to antibiotics including immunotherapies, precision antibiotics, and much more.
Download the brochure on the event website to view the agenda and speaker line-up at http://www.superbugssuperdrugs.com/pharphorpr.
Book your place before 14th December to save £200, or 31st January to save £100.
Superbugs & Superdrugs
18th & 19th March 2019
---- END ----
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk